| 1 |
NCT03430869 |
Not yet recruiting |
Pathophysiology of Neurodegeneration in Late-life Depression (AV45+THK) |
- Major Depressive Disorder
|
- Drug: F-18 AV-45
- Drug: F-18-THK-5351
|
Interventional
|
Phase 2 |
- Chang Gung Memorial Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- The standard uptake value ratio (SUVR) of 18F-florbetapir
- The standard uptake value ratio (SUVR) of 18F-THK-5351
|
60 |
All |
50 Years to 90 Years (Adult, Older Adult) |
NCT03430869 |
201601655A0 |
|
March 23, 2018 |
December 31, 2020 |
December 31, 2020 |
February 13, 2018 |
February 26, 2018 |
|
|
|
| 2 |
NCT01568307 |
Recruiting |
Major Depressive Disorder - Understanding The Link Between The Brain And The Heart |
- Major Depressive Disorder
|
- Drug: Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.
|
Interventional
|
Phase 4 |
- Baker IDI Heart and Diabetes Institute
- The Alfred
- Monash Medical Centre
- Ballarat Health Services
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of MDD patients carrying the s allele of the 5-HTT transporter that have higher sympathetic activity than homozygous ll patients.
- To determine the association between sympathetic activity and left ventricular hypertrophy.
- Change from baseline in the magnitude of morning surge in blood pressure.
- (and 2 more...)
|
80 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01568307 |
74/12
1022791 |
MDD |
May 2012 |
December 2020 |
December 2020 |
April 2, 2012 |
November 5, 2018 |
|
- Ballarat Health Service Psychiatric Services
Ballarat, Victoria, Australia - Monash Medical Centre - Monash Health
Clayton, Victoria, Australia - Alfred and Baker Medical Unit - Alfred Hospital
Melbourne, Victoria, Australia - Baker IDI Heart & Diabetes Institute
Melbourne, Victoria, Australia
|
|
| 3 |
NCT00296517 |
Completed
Has Results |
Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake Inhibitors |
|
- Drug: 323U66 (Bupropion Hydrochloride Sustained Release)
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in the Hamilton Depression Scale (HAM-D 17 Items) Total Score
- Hamilton Depression Scale (HAM-D 17 Items) Total Score
- Change From Baseline in the Hamilton Depression Scale (HAM-D 17 Items) Total Score at Week 8 and Total Score at Week 12
- (and 9 more...)
|
325 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00296517 |
AK1102365 |
|
January 19, 2006 |
March 1, 2008 |
March 28, 2008 |
February 27, 2006 |
September 25, 2018 |
July 16, 2009 |
- GSK Investigational Site
Aichi, Japan - GSK Investigational Site
Aichi, Japan - GSK Investigational Site
Aichi, Japan - (and 67 more...)
|
|
| 4 |
NCT02014363 |
Completed
Has Results |
Safety and Efficacy Study Comparing ETS6103 With Amitriptyline in the Treatment of Major Depressive Disorder (MDD) |
- Major Depressive Disorder
|
- Drug: ETS6103 (low dose)
- Drug: ETS6103 (high dose)
- Drug: Amitriptyline
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in Baseline-adjusted (Montgomery-Asberg Depression Scale) MADRS Score at the End of Treatment.
|
164 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02014363 |
ETS6103-003
2013-000719-26 |
ETS6103-003 |
October 2013 |
October 2015 |
October 2015 |
December 18, 2013 |
January 11, 2017 |
January 11, 2017 |
- CPS Research
Glasgow, Scotland, United Kingdom
|
|
| 5 |
NCT00955474 |
Terminated
Has Results |
Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms |
- Major Depressive Disorder With Psychotic Features
|
- Drug: Quetiapine
- Drug: escitalopram
- Drug: Sertraline
- Drug: Citalopram
|
Interventional
|
Phase 4 |
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Depression
- Psychosis
- Fasting Blood Glucose
- (and 12 more...)
|
32 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT00955474 |
2008P001022 |
Seroquel |
September 2008 |
January 2013 |
January 2013 |
August 10, 2009 |
April 20, 2017 |
March 28, 2016 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 6 |
NCT00168493 |
Unknown † |
The Neurobiology of Depressive Illness |
|
- Drug: antidepressants primarily selective serotonin reuptake inhibitors
|
Interventional
|
Not Applicable |
- Baker Heart Research Institute
- National Health and Medical Research Council, Australia
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- level of sympathetic nervous system activity and its response to treatment
- clinical response to treatment
|
40 |
Female |
18 Years to 75 Years (Adult, Older Adult) |
NCT00168493 |
NHMRC D-01 |
|
June 2000 |
December 2008 |
December 2009 |
September 15, 2005 |
May 20, 2008 |
|
- Baker Heart Research Institute
Melbourne, Victoria, Australia
|
|
| 7 |
NCT00953745 |
Completed
Has Results |
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression |
- Major Depressive Disorder
|
- Drug: Escitalopram
- Drug: Aripiprazole
- Drug: Placebo Capsule
- Drug: Placebo Tablet
|
Interventional
|
Not Applicable |
- Washington University School of Medicine
- Bristol-Myers Squibb
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Other
|
- Fluorodopa Uptake Values in Brain Images of Aripiprazole Augmentation Responders
- Depression Symptom Change on The Montgomery-Åsberg Depression Rating (MADRS) Scale Between ARP Responders and Non-responders.
|
43 |
All |
18 Years to 55 Years (Adult) |
NCT00953745 |
201101790-2 |
|
May 2009 |
June 2012 |
December 2012 |
August 6, 2009 |
April 19, 2018 |
April 19, 2018 |
- Washington University in St. Louis, School of Medicine
Saint Louis, Missouri, United States
|
|
| 8 |
NCT01579942 |
Terminated |
Potential Use Of Brain Network Activation Analysis to Diagnose Major Depression |
- Major Depressive Disorder
|
|
Observational
|
|
- Massachusetts General Hospital
- ElMindA Ltd
|
Other / Industry |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Brain Network Analysis group patterns
- Identify possible predictors of treatment response
|
70 |
All |
18 Years to 55 Years (Adult) |
NCT01579942 |
2011P000200 |
|
April 2012 |
|
|
April 18, 2012 |
March 6, 2017 |
|
- Depression Clinical and Research Program
Boston, Massachusetts, United States
|
|
| 9 |
NCT01175616 |
Withdrawn |
Creatine Augmentation in Veterans With SSRI-Resistant Major Depression |
- Major Depressive Disorder
|
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score
- Changes in 3T 31Phosphorus Magnetic Resonance Spectroscopy metabolites
|
0 |
All |
18 Years to 55 Years (Adult) |
NCT01175616 |
00041936 |
|
September 2012 |
April 2014 |
April 2014 |
August 5, 2010 |
August 15, 2016 |
|
|
|
| 10 |
NCT00229645 |
Completed |
A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and of Quetiapine Fumarate (Seroquel®) as Potentiation SSRI's, and SNRI's Treatment in Major Depression With Anxiety |
- Major Depression With Comorbid Anxiety Symptoms
|
- Drug: Quetiapine Fumarate (Seroquel®)
|
Interventional
|
Phase 4 |
- Dr Alexander McIntyre Inc.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- To compare the efficacy of quetiapine versus placebo over 8 weeks as an adjunctive agent for unipolar non-psychotic adult outpatients on SSRI or SNRI therapy with residual symptoms of depression and comorbid anxiety symptoms. This will be measured by the
- 1. Hamilton Depression Scale (HAM-D) total score,
- 2. Hamilton Anxiety Scale (HAM-A) total score
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00229645 |
D1441C00017 |
|
November 2003 |
|
April 2005 |
September 30, 2005 |
July 13, 2016 |
|
- Dr. A. McIntyre
Penticton, British Columbia, Canada
|
|
| 11 |
NCT02049385 |
Terminated
Has Results |
Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression? |
|
- Drug: Diazoxide
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- National Institute of Mental Health (NIMH)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
10 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02049385 |
140041
14-M-0041 |
|
January 3, 2014 |
July 21, 2016 |
July 21, 2016 |
January 30, 2014 |
October 13, 2017 |
October 13, 2017 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 12 |
NCT00955955 |
Completed
Has Results |
Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder |
|
- Other: 6(S)-5-MTHF(Deplin)
- Other: Placebo
|
Interventional
|
Phase 4 |
- George I. Papakostas
- Pamlab, L.L.C.
- Massachusetts General Hospital
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The 17-item Hamilton Depression Scale (HAM-D-17)
- The Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)
|
75 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00955955 |
2006P000604 (2) |
TRD-2 |
July 2009 |
April 2011 |
April 2011 |
August 10, 2009 |
April 28, 2017 |
January 18, 2013 |
- University of California San Diego School of Medicine
San Diego, California, United States - Rush University Medical Center, Psychiatric Medicine Associates, LLC
Chicago, Illinois, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - (and 3 more...)
|
|
| 13 |
NCT01197508 |
Completed
Has Results |
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder. |
- Major Depressive Disorder
|
- Drug: TC-5214
- Drug: Placebo
|
Interventional
|
Phase 3 |
- AstraZeneca
- Targacept Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.
- Response in Depressive Symptoms of Major Depressive Disorder (MDD), Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score at End of Treatment (Week 16)
- Remission in Depressive Symptoms of MDD, Defined as MADRS Total Score of ≤8 at End of Treatment (Week 16)
- (and 19 more...)
|
696 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01197508 |
D4130C00005 |
|
September 2010 |
January 2012 |
January 2012 |
September 9, 2010 |
April 11, 2014 |
October 29, 2012 |
- Research Site
Buenos Aires, Caba, Argentina - Research Site
Ciudad Autonoma Bs As, Cba, Argentina - Research Site
Dublin, Argentina - (and 84 more...)
|
|
| 14 |
NCT01106313 |
Completed |
Insulin Resistance in Patients With Major Depression |
- Depression
- Bipolar Disorder
- Mood Disorders
- (and 3 more...)
|
|
Observational
|
|
- Stanford University
- American Diabetes Association
|
Other |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- To quantify insulin-mediated glucose uptake as assessed by the SSPG concentration in patients with depression and compare the values to those previously obtained in a healthy age-matched control population
- To examine the association between insulin resistance and cognitive performance and clinical course of depression in patients with depression
|
57 |
All |
20 Years to 65 Years (Adult, Older Adult) |
NCT01106313 |
SU-02172010-5003
eProtocol 17089 |
|
July 2009 |
January 2016 |
January 2016 |
April 19, 2010 |
October 4, 2017 |
|
- Stanford University School of Medicine
Stanford, California, United States
|
|
| 15 |
NCT01282632 |
Completed |
Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression |
- Subjects Had Unipolar, Non-psychotic Major Depression
|
- Drug: Risperidone
- Drug: Olanzapine
|
Interventional
|
Phase 1
Phase 2 |
- Sunnybrook Health Sciences Centre
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from Baseline in Hamilton Depression Rating Scale at 1 week
- Change from Baseline in Montgomery Asberg Depression Scale (MADRS)at 1 week
- Change from baseline Hamilton Rating Scale for Anxiety (HAM-A) at 1 week
- (and 17 more...)
|
42 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01282632 |
ro123 |
|
August 2002 |
March 2004 |
March 2004 |
January 25, 2011 |
January 25, 2011 |
|
- Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
|
|
| 16 |
NCT01180400 |
Completed
Has Results |
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder |
- Major Depressive Disorder
- Depression
|
- Drug: TC-5214
- Drug: Placebo
|
Interventional
|
Phase 3 |
- AstraZeneca
- Targacept Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.
- Response in Depressive Symptoms of Major Depressive Disorder (MDD), Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score at End of Treatment (Week 16)
- Remission in Depressive Symptoms of MDD, Defined as MADRS Total Score of ≤8 at End of Treatment (Week 16)
- (and 18 more...)
|
295 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01180400 |
D4130C00003 |
|
September 2010 |
September 2011 |
September 2011 |
August 12, 2010 |
April 11, 2014 |
November 20, 2012 |
- Research Site
Brno, Czech Republic - Research Site
Kutna Hora, Czech Republic - Research Site
Litomerice, Czech Republic - (and 67 more...)
|
|
| 17 |
NCT01157078 |
Completed
Has Results |
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD) |
- Major Depressive Disorder
- Depression
|
- Drug: TC-5214
- Drug: Placebo
|
Interventional
|
Phase 3 |
- AstraZeneca
- Targacept Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.
- Response in Depressive Symptoms of Major Depressive Disorder (MDD), Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score at End of Treatment (Week 16)
- Remission in Depressive Symptoms of MDD, Defined as MADRS Total Score of ≤8 at End of Treatment (Week 16)
- (and 19 more...)
|
319 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01157078 |
D4130C00002 |
|
June 2010 |
November 2011 |
November 2011 |
July 5, 2010 |
April 11, 2014 |
November 20, 2012 |
- Research Site
Tuscaloosa, Alabama, United States - Research Site
Tucson, Arizona, United States - Research Site
Little Rock, Arkansas, United States - (and 48 more...)
|
|
| 18 |
NCT03026309 |
Not yet recruiting |
PET-MRI F-DOPA Activity in the Mesocorticolimbic System and Depressive Symptoms in the Prediction of Treatment Compatibility |
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine ([18F] FDOPA) uptake rate constant (K(i)) that reflects L-dopa transport.
|
60 |
Male |
30 Years to 50 Years (Adult) |
NCT03026309 |
0112-16-ASMC |
|
March 2017 |
March 2019 |
March 2019 |
January 20, 2017 |
January 20, 2017 |
|
|
|
| 19 |
NCT02134808 |
Active, not recruiting |
Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Creatine
- Drug: Placebo
|
Interventional
|
Phase 4 |
- Perry Renshaw
- University of Utah
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Brain phosphocreatine (PCr) concentrations
- Children's Depression Rating Scale-Revised (CDRS-R); Montgomery-Asberg Depression Rating Scale (MADRS)
|
71 |
Female |
12 Years to 21 Years (Child, Adult) |
NCT02134808 |
00073442 |
|
March 15, 2017 |
February 2021 |
February 2021 |
May 9, 2014 |
December 7, 2017 |
|
- University of Utah School of Medicine
Salt Lake City, Utah, United States
|
|
| 20 |
NCT01114334 |
Completed
Has Results |
Motivational Interviews for Depression in Primary Care |
|
- Behavioral: Guideline-Based Medical Management
- Behavioral: Motivational Interviewing for Depression
|
Interventional
|
Not Applicable |
- Denver Health and Hospital Authority
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Health Services Research
|
- Depression Remission
- Adherence to Treatment With Antidepressant Medication
- Patient Health Questionnaire-9 Instrument for Assessing Depressive Symptoms
|
168 |
All |
18 Years and older (Adult, Older Adult) |
NCT01114334 |
K23MH082997 |
|
April 2010 |
December 2012 |
December 2012 |
May 3, 2010 |
June 6, 2018 |
April 20, 2017 |
- Denver Health and Hospital Authority
Denver, Colorado, United States
|
|
| 21 |
NCT01454635 |
Completed |
Analisis of Facors Involved in Antidepressant Treatment Response of Major Depressive Disorder |
- Major Depressive Disorder
|
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hamilton Rating Scale for Depression
|
96 |
All |
20 Years and older (Adult, Older Adult) |
NCT01454635 |
SU-GEC-84 |
AFADTRMDD |
June 2008 |
March 2010 |
March 2010 |
October 19, 2011 |
October 31, 2011 |
|
- Showa University Northern Yokohama Hospital
Yokohama, Kanagawa, Japan
|
|
| 22 |
NCT01153347 |
Completed
Has Results |
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder |
- Major Depressive Disorder
- Depression
|
- Drug: TC-5214
- Drug: Placebo
|
Interventional
|
Phase 3 |
- AstraZeneca
- Targacept Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.
- Response in Depressive Symptoms of Major Depressive Disorder (MDD), Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score at End of Treatment (Week 16)
- Remission in Depressive Symptoms of MDD, Defined as MADRS Total Score of ≤8 at End of Treatment (Week 16)
- (and 20 more...)
|
2409 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01153347 |
D4130C00004 |
|
June 2010 |
January 2012 |
January 2012 |
June 30, 2010 |
April 11, 2014 |
November 20, 2012 |
- Research Site
Birmingham, Alabama, United States - Research Site
Tucson, Arizona, United States - Research Site
Conway, Arkansas, United States - (and 96 more...)
|
|
| 23 |
NCT00049972 |
Completed |
Major Depressive Disorder Study In Adults |
- Major Depressive Disorder
|
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Non-Randomized
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The proportion of patients who prematurely terminated treatment due to treatment emergent adverse events
- Recurrence rates of adverse events causing intolerability of previous SSRI/SNRI, Adverse event incidence rates, Mean change from baseline in the Beck Depression Inventory-II total score, Proportion of responsers based on teh CGI Global Improvement Item
|
646 |
All |
18 Years and older (Adult, Older Adult) |
NCT00049972 |
SB29060.833 |
|
September 2002 |
September 2003 |
September 2003 |
November 19, 2002 |
September 11, 2017 |
|
- GSK Clinical Trial Call Center
Birmingham, Alabama, United States - GSK Clinical Trial Call Center
Birmingham, Alabama, United States - GSK Clinical Trial Call Center
Fairfield, Alabama, United States - (and 68 more...)
|
|
| 24 |
NCT00873795 |
Completed |
Compare the Efficacy and Tolerability of the Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitors (SSRIs) Used in Major Depression |
- Major Depressive Disorder
|
- Drug: aripiprazole , sertraline
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- score change of Hamilton Rating Scale For Depression (HAM-D17 )
- score change of Brief Psychiatric Rating Scale (BPRS-50)
|
41 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00873795 |
IRB 09603-001 |
|
April 2007 |
March 2009 |
March 2009 |
April 2, 2009 |
April 2, 2009 |
|
- Psychiatry Department, Chimei Medical Center
Tainan, Taiwan
|
|
| 25 |
NCT01962753 |
Unknown † |
Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives Symptoms and Amyloïd Plaques (ASAP) |
|
|
Interventional
|
Not Applicable |
- University Hospital, Tours
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- standards uptakes values (SUVr)
- Residual cognitive deficits
|
150 |
All |
55 Years and older (Adult, Older Adult) |
NCT01962753 |
PHRN10-VC/ ASAP |
ASAP |
May 2012 |
May 2018 |
May 2018 |
October 14, 2013 |
February 16, 2015 |
|
- University Hospital of Besançon- Jean Minjoz
Besançon, France - University Hospital of Caen
Caen, France - University Hospital of Lille
Lille, France - (and 6 more...)
|
|
| 26 |
NCT00321152 |
Completed |
A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD) |
- Major Depressive Disorder
|
- Other: 6(S)-5-MTHF (a Medical Food)
|
Interventional
|
Phase 4 |
- Massachusetts General Hospital
- Pamlab, L.L.C.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
150 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00321152 |
2006P000604 |
|
November 2006 |
August 2008 |
June 2010 |
May 3, 2006 |
June 8, 2010 |
|
- University of California San Diego School of Medicine
San Diego, California, United States - Rush University Medical Center, Psychiatric Medicine Associates, LLC
Chicago, Illinois, United States - Lousiana State University Health Sciences Center
New Orleans, Louisiana, United States - (and 8 more...)
|
|
| 27 |
NCT00633399 |
Completed
Has Results |
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs |
- Major Depressive Disorder
|
- Drug: Ziprasidone
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Massachusetts General Hospital
- University of Alabama at Birmingham
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The Primary Outcome Measure Will be Response Rates (50% Decrease in HAM-D-17 Scores) During Phase 2
- Remission Rates (HAM-D 17 Scores of Less Than 8) After Treatment Phase 2.
- Comparing Scores on HAM-D 17 Baseline Visit to Phase 2 Final Visit at Week 8
|
458 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00633399 |
2007-P-002361 |
|
July 2008 |
March 2014 |
March 2014 |
March 12, 2008 |
July 3, 2014 |
July 3, 2014 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Massachusetts General Hospital- Depression Clinical and Research Program
Boston, Massachusetts, United States
|
|
| 28 |
NCT01185340 |
Completed
Has Results |
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor |
- Major Depressive Disorder
|
- Drug: LY2216684
- Drug: Placebo
- Drug: SSRI
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
- Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Global Functional Impairment Score
- Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Impact Subscale Score
- (and 16 more...)
|
1056 |
All |
18 Years and older (Adult, Older Adult) |
NCT01185340 |
12183
H9P-MC-LNBR |
|
March 2011 |
April 2013 |
April 2013 |
August 19, 2010 |
April 27, 2018 |
April 27, 2018 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Garden Grove, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Oakland, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Temecula, California, United States - (and 46 more...)
|
|
| 29 |
NCT00556140 |
Completed
Has Results |
The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression |
|
|
Interventional
|
Phase 3 |
- Massachusetts General Hospital
- Bristol-Myers Squibb
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Depression and Psychosis Response Rate
- Depression and Psychosis Remission Rate
|
16 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00556140 |
2003-P-000990 |
Abilify |
June 2003 |
January 2008 |
January 2008 |
November 9, 2007 |
August 20, 2012 |
August 20, 2012 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 30 |
NCT00086307 |
Completed
Has Results |
Lexapro and Pramipexole and to Treat Major Depression |
|
- Drug: Pramipexole
- Drug: Escitalopram
|
Interventional
|
Phase 2 |
- National Institute of Mental Health (NIMH)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Montgomery Asberg Depression Rating Scale (MADRS)
|
39 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00086307 |
040227
04-M-0227 |
|
June 2004 |
March 2010 |
March 2010 |
June 30, 2004 |
January 28, 2013 |
July 12, 2012 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 31 |
NCT00812812 |
Terminated
Has Results |
Paxil Japanese Post Marketing Paediatric Study in Depression (Double-blind, Placebo Controlled Study) |
|
- Drug: paroxetine 10mg tablet
- Drug: paroxetine 20mg tablet
- Drug: matched placebo to paroxetine 10mg
- Drug: matched placebo to paroxetine 20mg
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in the Children's Depression Rating Scale -Revised (CDRS-R) Total Score at Week 8
- Change From Baseline in the CDRS-R Total Score at Weeks 1, 2, 3, 4, and 6
- Number of Clinical Global Impression - Global Improvement (CGI-GI) Responders at Weeks 1, 2, 3, 4, 6, and 8
- (and 2 more...)
|
56 |
All |
7 Years to 17 Years (Child) |
NCT00812812 |
112487 |
|
March 2009 |
February 2011 |
February 2011 |
December 22, 2008 |
January 13, 2017 |
October 13, 2011 |
- GSK Investigational Site
Aichi, Japan - GSK Investigational Site
Aichi, Japan - GSK Investigational Site
Aichi, Japan - (and 30 more...)
|
|
| 32 |
NCT02805439 |
Completed |
Efficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment in Depressed Patients Not Fully Recovered From Depressive Symptoms With a Current Antidepressant Treatment |
- Major Depressive Disorder
|
- Drug: S47445 15mg
- Drug: S47445 50mg
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale (HAM-D) total score expressed as change from baseline value
- HAM-D total score
- Response to treatment defined by HAM-D total score decrease from baseline ≥ 50%
- (and 10 more...)
|
400 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02805439 |
CL2-47445-014
2015-003867-13 |
|
March 2016 |
April 2017 |
April 2017 |
June 20, 2016 |
April 24, 2018 |
|
- Mental Health Centre - Plovdiv
Plovdiv, Bulgaria - Mental Health Centre - Sofia district
Sofia, Bulgaria - Military Medical Academy, MHAT - Sofia
Sofia, Bulgaria - (and 50 more...)
|
|
| 33 |
NCT00840034 |
Completed
Has Results |
A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder |
- Depressive Disorder, Major
|
- Drug: LY2216684
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline to 8 Weeks in Montgomery-Asberg Depression Rating Scale (MADRS)
- Change From Baseline to 8 Weeks in 16-Item Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-SR16) Total Score
- Change From Baseline to 8 Weeks in 16-Item Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-SR16) Individual Items
- (and 10 more...)
|
227 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00840034 |
12850
H9P-MC-LNDK |
|
February 2009 |
January 2010 |
January 2010 |
February 10, 2009 |
April 24, 2018 |
April 24, 2018 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Birmingham, Alabama, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Little Rock, Arkansas, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Carson, California, United States - (and 21 more...)
|
|
| 34 |
NCT01370499 |
Completed
Has Results |
A Study of LY2216684 in Participants With Major Depression Disorder |
- Major Depressive Disorder
|
- Drug: LY2216684
- Drug: SSRI
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Clinically Significant Events
- Percentage of Participants With Suicidal Behaviors and Ideations Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)
- Change From Baseline to 52 Week Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score and Individual Items
- (and 10 more...)
|
288 |
All |
18 Years and older (Adult, Older Adult) |
NCT01370499 |
12849
H9P-JE-LNDJ |
|
August 2011 |
January 2014 |
January 2014 |
June 10, 2011 |
October 25, 2018 |
October 25, 2018 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Chiba, Japan - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Fukuoka, Japan - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Fukushima, Japan - (and 6 more...)
|
|
| 35 |
NCT01299272 |
Completed
Has Results |
A Study in Prevention of Re-emergence of Depression Symptoms |
- Major Depressive Disorder
|
- Drug: LY2216684
- Drug: Placebo
- Drug: SSRI
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of Participants Who Meet Criteria for Re-emergence of Depressive Symptoms Estimated by Kaplan-Meier Product Limit Method (Double-blind Randomized Withdrawal Period)
- Percentage of Participants With Re-emergence of Depressive Symptoms (Double-blind Randomized Withdrawal Period)
- Change From Randomization in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score and Individual Item Scores at Week 44 (Double-blind Randomized Withdrawal Period)
- (and 26 more...)
|
1249 |
All |
18 Years and older (Adult, Older Adult) |
NCT01299272 |
11317
H9P-MC-LNBN |
|
May 2011 |
November 2013 |
November 2013 |
February 18, 2011 |
April 17, 2018 |
April 17, 2018 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Redlands, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Sherman Oaks, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Wildomar, California, United States - (and 74 more...)
|
|
| 36 |
NCT01152554 |
Completed
Has Results |
A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder |
- Major Depressive Disorder
- MDD
- Depression
|
- Drug: TC-5214
- Drug: Placebo
|
Interventional
|
Phase 3 |
- AstraZeneca
- Targacept Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Frequency of Patients Experiencing at Least One Adverse Event (AE)
- Frequency of Patients Experiencing AEs That Resulted in Discontinuation of Investigational Product (IP)
- Frequency of Patients Experiencing Serious Adverse Events (SAEs)
- (and 6 more...)
|
813 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01152554 |
D4130C00007 |
|
June 2010 |
February 2012 |
February 2012 |
June 29, 2010 |
April 11, 2014 |
October 29, 2012 |
- Research Site
Birmingham, Alabama, United States - Research Site
Tuscaloosa, Alabama, United States - Research Site
Tucson, Arizona, United States - (and 91 more...)
|
|
| 37 |
NCT00157547 |
Completed |
Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Depression |
- Major Depressive Disorder
|
- Drug: Selective serotonin reuptake inhibitors (SSRI)
|
Interventional
|
Phase 4 |
- Massachusetts General Hospital
- Medtronic - MITG
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
95 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00157547 |
2002-P-001784 |
|
April 2003 |
August 2006 |
August 2006 |
September 12, 2005 |
May 28, 2008 |
|
|
|
| 38 |
NCT01173601 |
Completed
Has Results |
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: LY2216684
- Drug: Placebo
- Drug: SSRI
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Randomization to Week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
- Change From Randomization to Week 8 in Sheehan Disability Scale (SDS) Global Functional Impairment Scale
- Change From Randomization to Week 8 in Fatigue Associated With Depression (FAsD) Impact Subscale Score
- (and 18 more...)
|
1416 |
All |
18 Years and older (Adult, Older Adult) |
NCT01173601 |
11316
H9P-MC-LNBM |
|
November 2010 |
October 2013 |
October 2013 |
August 2, 2010 |
April 17, 2018 |
April 17, 2018 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Irvine, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
La Habra, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Redlands, California, United States - (and 60 more...)
|
|
| 39 |
NCT01221935 |
Completed |
Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder |
- Major Depressive Disorder
|
- Other: Pristiq first-line treatment charts
- Other: Pristiq second-line treatment charts
- Other: SNRI or SSRI first-line treatment charts
- Other: SNRI or SSRI second-line treatment charts
|
Observational
|
|
|
Industry |
- Time Perspective: Retrospective
|
- 300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment.
- 800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a SNRI or SSRI).
- 800 charts including patients initiated on a SNRI or SSRI (excluding Pristiq) within the past 6 months as a first-line treatment.
- (and 6 more...)
|
2701 |
All |
18 Years and older (Adult, Older Adult) |
NCT01221935 |
3151A1-4431
B2061039 |
|
September 2009 |
January 2010 |
January 2010 |
October 18, 2010 |
January 26, 2011 |
|
|
|
| 40 |
NCT00043550 |
Completed
Has Results |
Treatments for Depression: Drug Versus Psychotherapy |
|
- Behavioral: Supportive Expressive Therapy
- Drug: Sertraline
- Drug: Pill Placebo
- Drug: Venlafaxine
|
Interventional
|
Phase 3 |
- University of Pennsylvania
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Rating Scale for Depression-17 Item
|
156 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00043550 |
R01MH061410
DSIR 83-ATAS |
|
November 2001 |
June 2009 |
June 2009 |
August 12, 2002 |
June 2, 2017 |
June 2, 2017 |
- University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
|
| 41 |
NCT00733668 |
Completed |
Efficacy of SEROQUEL in Selective Serotonin Reuptake Inhibitors (SSRI)-Resistant Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Quetiapine fumarate (Seroquel)
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The Montgomery-Asberg Depression Scale (MADRS) score
- The Brief psychiatric Rating Scale (BPRS) scoreThe Clinical Global impression (CGI) scorePatient reported outcomes (PROs)
- Sheehan Disability Scale (SDS) score
- The Symptom Checklist 90 Revisred (SCL-90-R) score
|
|
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00733668 |
D1449C00009 |
UNIQUE |
March 2006 |
November 2007 |
November 2007 |
August 13, 2008 |
March 25, 2009 |
|
- Research Site
Brugge, Belgium - Research Site
Leuven, Belgium - Research Site
Liege, Belgium - Research Site
Sint-Truiden, Belgium
|
|
| 42 |
NCT01187407 |
Completed
Has Results |
A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment |
- Major Depressive Disorder (MDD)
|
- Drug: LY2216684
- Drug: Placebo
- Drug: SSRI
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Randomization to Week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
- Change From Randomization to Week 8 in the Sheehan Disability Scale (SDS) Global Functional Impairment Score
- Change From Randomization to Week 8 in the Fatigue Associated With Depression (FAsD) Impact Subscale Score
- (and 17 more...)
|
1480 |
All |
18 Years and older (Adult, Older Adult) |
NCT01187407 |
12182
H9P-MC-LNBQ |
|
March 2011 |
August 2013 |
August 2013 |
August 24, 2010 |
April 24, 2018 |
April 24, 2018 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Birmingham, Alabama, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Phoenix, Arizona, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Chino, California, United States - (and 51 more...)
|
|
| 43 |
NCT00000378 |
Completed
Has Results |
Antidepressant Treatment of Melancholia in Late Life |
|
- Drug: Sertraline
- Drug: Nortriptyline
|
Interventional
|
Phase 4 |
- New York State Psychiatric Institute
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- HAMILTON Rating Scale for DEPRESSION Range
|
110 |
All |
60 Years to 95 Years (Adult, Older Adult) |
NCT00000378 |
#3105
R01MH055716 |
|
July 1997 |
June 2002 |
June 2002 |
November 3, 1999 |
October 7, 2015 |
April 21, 2015 |
- 1051 Riverside Drive
New York, New York, United States
|
|
| 44 |
NCT02969876 |
Recruiting |
Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine |
- Depressive Disorder
- Major Depression
- Depression
- Depression, Unipolar
|
|
Interventional
|
Phase 4 |
- Massachusetts General Hospital
- Takeda
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Mnemonic Similarity Task
- Brain Derived Neurotrophic Factors Levels in the Blood
- Quick Inventory of Depressive Symptomatology
- (and 2 more...)
|
20 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02969876 |
2016P001243 |
VOR-IISR |
August 24, 2017 |
November 2018 |
November 2018 |
November 21, 2016 |
May 15, 2018 |
|
- the Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 45 |
NCT02720198 |
Completed |
Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD |
- Major Depressive Disorder
|
- Drug: Levomilnacipran
- Drug: Quetiapine
|
Interventional
|
Phase 3 |
- Duke University
- Forest Laboratories
- Institute for Advanced Medical Research, Alpharetta, GA
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Changes of Montgomery-Åsberg Depression Rating Scale (MADRS) total score
- Response Rate
- Remission Rate
- (and 8 more...)
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02720198 |
Pro00064983 |
|
January 23, 2017 |
June 12, 2018 |
June 12, 2018 |
March 25, 2016 |
June 19, 2018 |
|
- Institute for Advanced Medical Research
Alpharetta, Georgia, United States
|
|
| 46 |
NCT00361218 |
Completed
Has Results |
Biological Markers of Response to Treatment in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: open-label selective serotonin reuptake inhibitor (SSRI)
|
Interventional
|
Phase 3 |
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Serum Brain-derived Neurotrophic Factor (BDNF) Levels
- Quantitative Electroencephalogram (QEEG) Parameters as Predictors of Response
|
72 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00361218 |
2005P000413 |
|
October 2005 |
December 2008 |
December 2008 |
August 8, 2006 |
May 11, 2018 |
September 26, 2013 |
|
|
| 47 |
NCT02434393 |
Active, not recruiting |
Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project |
- Major Depression
- Late Life Depression (LLD)
|
|
Observational
|
|
- University of Southern California
- National Institute of Mental Health (NIMH)
- University of California, San Francisco
- Alzheimer's Therapeutic Research Institute
|
Other / NIH |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Rate of Change in neuropsychological measures of executive function as measured by the Digit Symbol Substitution Test using total correct.
- Rate of Change in expressive language as measured by the Boston Naming Test using total correct.
- Rate of change in learning and memory as measured by the Rey Auditory Verbal Learning Test using total correct and delayed recall.
- (and 3 more...)
|
133 |
All |
65 Years and older (Older Adult) |
NCT02434393 |
ADC-048
R01MH098062 |
ADNI-D |
March 4, 2015 |
January 2020 |
January 2021 |
May 5, 2015 |
December 8, 2017 |
|
- University of California, San Francisco
San Francisco, California, United States - University of Pittsburgh
Pittsburgh, Pennsylvania, United States
|
|
| 48 |
NCT02307617 |
Recruiting |
Glutamate Probes in Adolescent Depression |
- Major Depressive Disorder
- Major Depressive Disorder, Recurrent
- Major Depressive Disorder, Remitted
|
|
Observational
|
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Other
|
- Concentrations of GABA and glutamate in the brains of adolescents with MDD.
- The change of GABA and glutamate concentrations in adolescents with MDD after 6 weeks of SSRI treatment.
- The effect of glutamatergic and GABAergic functioning on human development in adolescents with MDD
- The effect of glutamatergic and GABAergic functioning on human development in adolescents with MDD after 6 weeks of SSRI treatment.
|
100 |
All |
13 Years to 21 Years (Child, Adult) |
NCT02307617 |
14-004662 |
GPII |
August 1, 2014 |
December 31, 2018 |
March 31, 2019 |
December 4, 2014 |
November 6, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 49 |
NCT00993876 |
Completed |
Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment |
- Cognitive Performance in Major Depression
|
- Drug: citalopram
- Drug: reboxetine
- Behavioral: interpersonal psychotherapy
|
Interventional
|
Not Applicable |
- Zentrum für Integrative Psychiatrie
- German Research Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- cognitive performance with respect to cognitive flexibility, memory and attention
- CREB-phosphorylation in T-Lymphocytes
|
45 |
All |
20 Years to 45 Years (Adult) |
NCT00993876 |
KO 2067 |
Decoflex |
August 2005 |
August 2008 |
August 2008 |
October 14, 2009 |
October 14, 2009 |
|
- Zentrum für Integrative Psychiatrie
Kiel, Germany
|
|
| 50 |
NCT02972398 |
Recruiting |
N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders |
- Major Depressive Disorders
|
- Drug: N-acetylcysteine
- Drug: placebo comparator of N-acetylcysteine
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The change from baseline Hamilton Depression Rating Scale (HAMD)-17 items at week2,4,6,8,10,and 12.
- The change from baseline HAMD-17 items at week14,16,18,and 20.
- The effects of augmentation treatment with NAC on scores in Beck Anxiety Inventory (BAI)
- (and 6 more...)
|
200 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02972398 |
NAC-2015-TJAH |
|
September 2015 |
September 2018 |
March 2019 |
November 23, 2016 |
April 25, 2018 |
|
- Tianjin Anding Hospital
Tianjin, Tianjin, China
|
|
| 51 |
NCT01155661 |
Completed
Has Results |
A Safety Study in Participants With Major Depressive Disorder |
- Depressive Disorder, Major
|
- Drug: LY2216684 (edivoxetine)
- Drug: SSRI
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The Number of Participants Experiencing Clinically Significant Effects
- Percent of Participants With Suicidal Ideation and Behavior Based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
- Change From Baseline to 54 Week Endpoint in the Arizona Sexual Experiences (ASEX) Scale
- (and 19 more...)
|
608 |
All |
18 Years and older (Adult, Older Adult) |
NCT01155661 |
11318
H9P-MC-LNBO |
|
October 2010 |
December 2012 |
December 2012 |
July 2, 2010 |
April 17, 2018 |
April 17, 2018 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Birmingham, Alabama, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Little Rock, Arkansas, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Cerritos, California, United States - (and 45 more...)
|
|
| 52 |
NCT01811147 |
Completed |
Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI |
- Bipolar Disorder
- Major Depression
|
- Drug: Selective Serotonin Reuptake Inhibitor (SSRI)
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Hamilton depression rating scale
- Young Mania Rating Scale
|
192 |
All |
15 Years to 30 Years (Child, Adult) |
NCT01811147 |
IRB 12-1279 |
|
November 2011 |
June 2018 |
June 2018 |
March 14, 2013 |
August 23, 2018 |
|
- Cleveland Clinic Foundation Center for Behavioral Health
Cleveland, Ohio, United States
|
|
| 53 |
NCT01263223 |
Completed
Has Results |
A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors |
- Major Depressive Disorder
|
- Drug: LY2216684
- Drug: Placebo
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Maximum and Mean Change From Baseline in Ambulatory Heart Rate on Day 1
- Maximum and Mean Change From Baseline in Ambulatory Heart Rate on Day 4
- Maximum and Mean Change From Baseline in Ambulatory Systolic and Diastolic Blood Pressure During Treatment With 18-mg LY2216684 or Placebo on Day 1
- (and 5 more...)
|
24 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01263223 |
12607
H9P-EW-LNCP |
|
December 2010 |
March 2011 |
March 2011 |
December 20, 2010 |
October 23, 2018 |
October 23, 2018 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Saint Louis, Missouri, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Austin, Texas, United States
|
|
| 54 |
NCT00787501 |
Completed |
Imaging Antidepressant vs. Cognitive Behavior Therapy Effects on Unipolar Depression |
- Major Depressive Disorder
|
- Drug: SSRI
- Behavioral: CBT
|
Interventional
|
Phase 1 |
- University of Pittsburgh
- The Pittsburgh Foundation
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Treatment outcome will be assessed on a variety of dimensions including change in symptoms, self-reported rumination, behavioral performance on cognitive tasks, and physiological reactivity to emotional information processing tasks.
|
98 |
All |
18 Years to 55 Years (Adult) |
NCT00787501 |
PRO07100326
M2007-0114
R01MH074807 |
ssrifMRI |
June 2008 |
July 2011 |
July 2011 |
November 7, 2008 |
February 4, 2016 |
|
- Mood Disorders Treatment and Research Program - UPMC
Pittsburgh, Pennsylvania, United States
|
|
| 55 |
NCT03554447 |
Active, not recruiting |
Role of Pentoxifylline as an Adjuvant Therapy for Adult Patients With Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Escitalopram 20 mg tablet plus Pentoxifylline 400Mg Tablet
- Drug: Escitalopram 20 mg tablet + Placebo
|
Interventional
|
Not Applicable |
- Mahmoud Samy Abdallah
- Sadat City University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Effect on Hamilton Depression rating scale score (HAM-D score)
- Effect on biological markers
|
80 |
All |
18 Years and older (Adult, Older Adult) |
NCT03554447 |
0074/2015 |
|
April 20, 2015 |
December 1, 2017 |
December 1, 2018 |
June 13, 2018 |
June 25, 2018 |
|
|
|
| 56 |
NCT00285935 |
Recruiting |
Cellular Aging and Neurobiology of Depression Study |
- Major Depressive Disorder
|
- Drug: Treatment with SSRI
|
Interventional
|
Phase 4 |
- University of California, San Francisco
- National Institutes of Health (NIH)
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Depression ratings at baseline and Week 8
- Serum levels of steroids and neurosteroids at baseline and Week 8
- Serum levels of oxidative stress markers at baseline and Week 8
- Serum levels of cytokines and immune markers at baseline and Week 8
|
228 |
All |
21 Years to 60 Years (Adult) |
NCT00285935 |
10-00825
R01MH083784 |
CAN-D |
December 2010 |
February 2020 |
February 2020 |
February 2, 2006 |
October 29, 2018 |
|
- University of California San Francisco
San Francisco, California, United States
|
|
| 57 |
NCT01318434 |
Completed |
A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) |
- Major Depressive Disorder
|
- Drug: EB-1010 25mg BID
- Drug: SSRI Active
- Drug: EB-1010 50mg BID
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Euthymics BioScience, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline in MADRS Score
- Change in Clinical Global Severity Scale
|
342 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01318434 |
EB-1010-301 |
|
February 2011 |
February 2013 |
February 2013 |
March 18, 2011 |
December 4, 2015 |
|
- Pacific Clinical Research Medical Group
Arcadia, California, United States - Southwest Research, Inc.
Beverly Hills, California, United States - Synergy Clinical Research Center
National City, California, United States - (and 40 more...)
|
|
| 58 |
NCT02469545 |
Completed |
Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment |
- Depression
- Anxiety Disorder
|
- Drug: Lactobacillus Plantarum 299v
- Drug: Crystalline cellulose powder
- Drug: Escitalopram
- Drug: Sertraline
|
Interventional
|
Phase 2 |
- Medical University of Bialystok
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Evaluation of psychometric parameters - Change in Hamilton Depression Rating Scale from baseline at 3 weeks and 8 weeks of the study.
- Evaluation of psychometric parameters - Change in Perceived Stress Scale (PSS-10) from baseline at 3 weeks and 8 weeks of the study.
- Evaluation of psychometric parameters - Change in Symptom Checklist 90 Scale (SCL-90) from baseline at 3 weeks and 8 weeks of the study.
- (and 8 more...)
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02469545 |
133-47818 |
|
June 2014 |
March 2016 |
March 2016 |
June 11, 2015 |
September 7, 2018 |
|
- Department of Psychiatry, Medical University of Bialystok
Bialystok, Poland
|
|
| 59 |
NCT02869035 |
Recruiting |
Treatment Outcome in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Escitalopram
- Drug: Duloxetine
|
Interventional
|
Phase 1 |
- Rigshospitalet, Denmark
- Center for Integrated Molecular Brain Imaging
- Psychiatric Centre Copenhagen
- Central Visitation, Region Hovedstaden
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Binary treatment outcome in terms of remission from depression.
- Baseline cerebral 5-HT4R binding as imaged by 11C-SB207145 PET.
- Changes from baseline in cerebral 5-HT4R binding as imaged by 11C-SB207145 PET
- (and 43 more...)
|
100 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02869035 |
NP1 |
|
August 2016 |
July 2019 |
July 2019 |
August 16, 2016 |
June 2, 2017 |
|
- Neurobiology Research Unit, Rigshospitalet
Copenhagen, Denmark
|
|
| 60 |
NCT02132286 |
Completed |
Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression |
- Major Depressive Disorder
|
- Drug: Quetiapine XR (extended release)
|
Interventional
|
Phase 4 |
- University of Calgary
- AstraZeneca
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
|
- Changes in amygdala responses to negative emotional faces from the pre-treatment baseline to 8 weeks post treatment.
- Changes in depression symptom severity as measured by Hamilton Depression Rating Scale from the pre-treatment baseline to week 8 post-treatment
|
57 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02132286 |
D1443L00037 |
|
December 2008 |
April 2012 |
April 2012 |
May 7, 2014 |
May 7, 2014 |
|
- University of Calgary: Foothills medical centre
Calgary, Alberta, Canada
|
|
| 61 |
NCT01598324 |
Terminated |
Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder |
- Treatment-Resistant Depression
|
|
Observational
|
|
- Mclean Hospital
- Pfizer
- Massachusetts General Hospital
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Glutamate level in antidepressant non-responders
- Glutamine level in treatment-responders following six weeks of antidepressant and non-responders following six weeks of adjunctive treatment.
- Glutamine level in treatment-responders following six weeks of antidepressant and non-responders following six weeks of adjunctive treatment
- (and 5 more...)
|
1 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01598324 |
WS2058787 |
|
July 2012 |
April 2013 |
|
May 15, 2012 |
August 13, 2013 |
|
- McLean Hospital - McLean Imaging Center
Belmont, Massachusetts, United States
|
|
| 62 |
NCT03055468 |
Not yet recruiting |
The Efficacy of Peer Support Model for Depression Care in Patients With Diabetes Mellitus |
- Diabetes Mellitus
- Depression
|
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Adequate glycaemic control
- Depression Clinical Remission
|
130 |
All |
18 Years and older (Adult, Older Adult) |
NCT03055468 |
MakerereU |
|
April 1, 2017 |
March 30, 2018 |
March 30, 2018 |
February 16, 2017 |
March 13, 2017 |
|
|
|
| 63 |
NCT02269540 |
Recruiting |
A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A) |
- Major Depressive Disorder
|
- Drug: Sertraline
- Drug: Citalopram
- Drug: N-acetylcysteine (NAC)
- Drug: Existing depression medication treatment
|
Interventional
|
Early Phase 1 |
- Centre for Addiction and Mental Health
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MAO-A distribution volume with positron emission tomography
- Hamilton Depression Rating Scale Score
- Magnetic Resonance Spectroscopy (n-acetylaspartate and glutathione levels)
- Blood markers of monoamine oxidase-A fragment level and glutathione level
|
18 |
All |
18 Years to 49 Years (Adult) |
NCT02269540 |
137/2013 |
|
October 2014 |
June 2018 |
July 2018 |
October 21, 2014 |
February 14, 2018 |
|
- Research Imaging Centre, Centre for Addiction and Mental Health
Toronto, Ontario, Canada
|
|
| 64 |
NCT00056472 |
Completed
Has Results |
Study of Pharmacotherapy of Psychotic Depression |
- Major Depressive Disorder With Psychotic Features
|
- Drug: Olanzapine
- Drug: Sertraline
- Other: placebo
|
Interventional
|
Phase 3 |
- Weill Medical College of Cornell University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Remission of Depression Hamilton Depression Scale (Ham-D) and Psychosis Schedule for Affective Disorders in Schizophrenia - Delusional Item (SADS) During the Course of the Trial
- Scores on CGI-S Compared to Baseline Over the Course of the Trial
|
259 |
All |
18 Years and older (Adult, Older Adult) |
NCT00056472 |
U01MH062624
U01MH062565
U01MH062518
U01MH062446 |
STOP-PD |
January 2003 |
June 2008 |
June 2008 |
March 17, 2003 |
August 2, 2013 |
August 2, 2013 |
- University of Massachusetts Medical School
Worcester, Massachusetts, United States - Cornell University
New York, New York, United States - University of Pittsburgh
Pittsburgh, Pennsylvania, United States - University of Toronto
Toronto, Ontario, Canada
|
|
| 65 |
NCT03321526 |
Recruiting |
A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy |
- Depressive Disorder, Major
|
- Drug: JNJ-42847922
- Drug: Placebo Matching to JNJ-42847922
- Drug: Quetiapine XR
- (and 3 more...)
|
Interventional
|
Phase 2 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Time to All-Cause Discontinuation of Study Drug
- Percentage of Participants Achieving Remission at Week 12 and Sustaining Remission at Weeks 18 and 24
- Percentage of Participants Achieving Response at Week 12 and Sustaining Response at Weeks 18 and 24
- (and 31 more...)
|
100 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03321526 |
CR108394
42847922MDD2002 |
|
December 12, 2017 |
December 10, 2018 |
April 15, 2019 |
October 25, 2017 |
October 22, 2018 |
|
- NoesisPharma Research
Phoenix, Arizona, United States - Clinical Research Consortium Arizona
Tempe, Arizona, United States - Woodland Research Northwest
Rogers, Arkansas, United States - (and 55 more...)
|
|
| 66 |
NCT02890212 |
Recruiting |
Selenium as Augmentation Treatment for Sertraline Resistant Major Depression |
|
- Dietary Supplement: selenium supplementation
- Dietary Supplement: placebo
|
Interventional
|
Not Applicable |
- University of Sao Paulo General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Depressive Rating Scale
- Montgomery-Asberg Depression Rating Scale
- Clinical Global Impression Scale
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT02890212 |
Selen-2015 |
|
August 2005 |
December 2018 |
December 2018 |
September 7, 2016 |
May 4, 2018 |
|
- Instituto de Psiquiatria - Hcfmusp
São Paulo, Brazil
|
|
| 67 |
NCT00561509 |
Completed |
Multi-Country Observational Study to Collect the Frequency of Sexual Dysfunction With Antidepressant Treatment, Either With SSRIs or Duals at 8 Weeks and 6 Months |
- Major Depressive Disorder
|
- Drug: SSRIs
- Drug: Dual antidepressants
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Frequency of sexual dysfunction due to treatment with either SSRIs or Dual antidepressants
- Frequency of sexual dysfunction along treatment with SSRIs or Dual antidepressants
- Disease severity
- (and 4 more...)
|
1626 |
All |
18 Years and older (Adult, Older Adult) |
NCT00561509 |
11539
F1J-MC-B019 |
|
November 2007 |
|
June 2009 |
November 21, 2007 |
July 15, 2009 |
|
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Innsbruck, Austria - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Jenbach, Austria - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Salzburg, Austria - (and 54 more...)
|
|
| 68 |
NCT00000375 |
Completed |
Continuation Electroconvulsive Therapy Vs Medication to Prevent Relapses in Patients With Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Nortriptyline-lithium (NOR-Li)
- Procedure: Bilateral electroconvulsive therapy (ECT)
- Drug: Continuation therapy
- Behavioral: Continuation ECT
|
Interventional
|
Phase 4 |
- National Institute of Mental Health (NIMH)
|
NIH |
- Allocation: Randomized
- Masking: Single
- Primary Purpose: Treatment
|
|
|
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00000375 |
MH55495 |
|
February 1997 |
|
|
November 3, 1999 |
December 20, 2005 |
|
- New Jersey Medical School
Newark, New Jersey, United States
|
|
| 69 |
NCT03466346 |
Not yet recruiting |
Depression And Primary-care Partnership for Effectiveness-implementation Research |
|
- Drug: Fluoxetine
- Behavioral: Interpersonal Psychotherapy
|
Interventional
|
Not Applicable |
- University of California, San Francisco
- University of Nairobi
- National Institute of Mental Health (NIMH)
- (and 3 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Health Services Research
|
- Change in the Mini International Psychiatric Interview (MINI) depression module
- Cost Effectiveness
- Cost Benefit
|
2000 |
All |
18 Years and older (Adult, Older Adult) |
NCT03466346 |
1U01MH115512 |
DAPPER |
June 2018 |
January 2023 |
June 2023 |
March 15, 2018 |
March 16, 2018 |
|
|
|
| 70 |
NCT02290496 |
Active, not recruiting |
CBT Insomnia Teens: Augmenting SSRIs to Improve Youth Depression |
|
- Behavioral: CBT for Insomnia (CBT-I)
- Behavioral: Sleep Hygiene (SH)
|
Interventional
|
Phase 3 |
- Kaiser Permanente
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Improvement in depression and current severity of depression
- Psychiatric Status Ratings (PSRs) for major depressive disorder (MDD)
- Increase in total sleep time across the study period
- (and 2 more...)
|
165 |
All |
12 Years to 19 Years (Child, Adult) |
NCT02290496 |
R01MH104647 |
SleepWell |
March 2015 |
March 2019 |
March 2019 |
November 14, 2014 |
September 1, 2017 |
|
- Kaiser Permanente Center for Health Research/Northwest
Portland, Oregon, United States
|
|
| 71 |
NCT00149071 |
Completed |
Transcranial Magnetic Stimulation (rTMS) Accelerates the Response to Escitalopram in Major Depression |
|
|
Interventional
|
Not Applicable |
- Hillerod Hospital, Denmark
- Medicon Valley Academy
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
|
61 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT00149071 |
1,2 |
|
March 2004 |
|
January 2006 |
September 8, 2005 |
November 5, 2007 |
|
- Psychiatric research unit, Hilleroed Hospital,
Hillerod, Denmark
|
|
| 72 |
NCT01001559 |
Completed
Has Results |
Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis |
- Major Depressive Disorder
|
- Drug: L-methylfolate
- Drug: Selective serotonin reuptake inhibitor (SSRI)
- Drug: Serotonin and norepinephrine reuptake inhibitor (SNRI)
|
Observational
|
|
- Pamlab, Inc.
- Red Oak Psychiatry Associates, PA
- Baylor Health Care System
|
Industry / Other |
- Observational Model: Case Control
- Time Perspective: Retrospective
|
- Improvement as Measured by Change in Clinical Global Impression of Severity (CGI-S) Rating From Baseline
- Length of Time to Peak Response, as Determined by the Clinical Global Impression of Severity (CGI-S) Scale
- Number of Hospitalizations Due to MDD
- Absolute Count of Alterations in Therapy Required, Such as Dose Increases, Antidepressant Substitutions, or Addition of Augmentation Medications
|
242 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01001559 |
Pamlab D-005 |
|
August 2009 |
December 2010 |
June 2011 |
October 26, 2009 |
December 19, 2013 |
December 19, 2013 |
- Red Oak Psychiatry Associates, PA
Houston, Texas, United States
|
|
| 73 |
NCT00208702 |
Completed |
Thyroid Medication and Antidepressants for Treating Major Depression |
|
- Drug: Triiodothyronine
- Other: Placebo
- Drug: Sertraline
|
Interventional
|
Phase 4 |
- Emory University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
|
153 |
All |
18 Years to 60 Years (Adult) |
NCT00208702 |
0431-1996
R01MH056946
431-1996
DSIR AT-SO |
|
September 1996 |
July 2003 |
July 2003 |
September 21, 2005 |
November 17, 2015 |
|
- Emory University
Atlanta, Georgia, United States
|
|
| 74 |
NCT02901249 |
Completed |
Cost- Effectiveness and Quality of Life Assessment in Major Depression Disorder |
|
- Drug: sertraline
- Drug: Nortriptyline
- Drug: Lithium Carbonate
|
Interventional
|
Phase 4 |
- Federal University of Rio Grande do Sul
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response to treatment
- Remission
- Quality of life
|
68 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02901249 |
017/2009 |
|
May 2010 |
November 2014 |
September 2015 |
September 15, 2016 |
September 15, 2016 |
|
|
|
| 75 |
NCT00510822 |
Completed |
Cimicoxib for the Treatment of Major Depression (SECIM) |
|
- Drug: Cimicoxib
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Affectis Pharmaceuticals AG
- FGK Clinical Research GmbH
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- • Mean change on the total score of the Hamilton Depression Rating Scale (HamD-17) from baseline to endpoint (Week 6).
- • Changes from baseline to interim weekly visits (week 1 to 5) in HamD-17 score • Clinical Global Impression (CGI) score • Montgomery Asberg Depression Rating Scale (MADRS) score • Response rate, remission rate and drop out rate. • Onset of
|
169 |
All |
18 Years to 60 Years (Adult) |
NCT00510822 |
AFX-01
EudraCT-No. 2007-001335-54 |
|
October 2007 |
February 2010 |
February 2010 |
August 2, 2007 |
November 13, 2013 |
|
- Landeskrankenhaus Klagenfurt, Abteilung für Psychiatrie und Psychotherapie
Klagenfurt, Austria - Gemeinnützige Salzburger Landeskliniken Betriebsgesellschaft mbH
Salzburg, Austria - Faculty Hospital Brno
Brno, Czech Republic - (and 22 more...)
|
|
| 76 |
NCT02023567 |
Unknown † |
Objective Diagnostic Markers and Personalized Intervention in MDD Patients |
- Depressive Disorder, Major
|
|
Interventional
|
Not Applicable |
- Peking University
- Capital Medical University
- Peking Union Medical College Hospital
- (and 6 more...)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- The changes of HAMD total score at 8 weeks from baseline
- The changes of HAMA total score at 8 weeks from baseline
- The change of CGI score at 8 weeks from baseline
- (and 2 more...)
|
2400 |
All |
18 Years to 55 Years (Adult) |
NCT02023567 |
2013CB531305 |
|
November 2013 |
December 2016 |
December 2016 |
December 30, 2013 |
May 20, 2016 |
|
- Beijing Anding Hospital
Beijing, Beijing, China - Peking Union Medical College Hospital
Beijing, Beijing, China - Peking University Sixth Hospital
Beijing, Beijing, China - (and 6 more...)
|
|
| 77 |
NCT02549547 |
Unknown † |
Jump Step - A Participatory Approach to Physical Activity & Mental Wellness |
- Major Depressive Disorder
- Bipolar, Depression
|
- Behavioral: Group Medical Visits
|
Interventional
|
Not Applicable |
- University of British Columbia
- Vancouver Foundation
- Mood Disorders Association of BC
- YMCA
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 'Jump Step Intervention Questionnaire'
- Physical Activity
- Patient Activation
- (and 3 more...)
|
80 |
All |
18 Years and older (Adult, Older Adult) |
NCT02549547 |
ID: H15-01932 |
JumpStep |
August 2015 |
January 2016 |
June 2017 |
September 15, 2015 |
September 15, 2015 |
|
- Centre for Hip Health & Mobility, Department of Family Practice
Vancouver, British Columbia, Canada - Mood Disorders Association of BC
Vancouver, British Columbia, Canada - Robert Lee YMCA
Vancouver, British Columbia, Canada
|
|
| 78 |
NCT01027559 |
Completed
Has Results |
fMRI Study of Treatment Changes in Major Depression |
- Major Depression
- Treatment
|
- Drug: Sertraline
- Behavioral: Cognitive Behavioral Therapy
|
Interventional
|
Not Applicable |
- Washington University School of Medicine
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Other
|
- Blood Oxygen-level Dependent Activations During an Emotional Distractor Task Between fMRI Scans of Depressed Participants in the CBT Group and Control Participants.
- Hamilton Depression Rating Scale Score at Baseline and 12 Weeks
|
97 |
All |
18 Years to 50 Years (Adult) |
NCT01027559 |
081348
R01MH064821
2R01MH064821-05A2
DDTR A3-NSI |
|
February 2009 |
January 2014 |
January 2014 |
December 8, 2009 |
July 17, 2018 |
June 13, 2018 |
- Washington University
Saint Louis, Missouri, United States
|
|
| 79 |
NCT01691092 |
Completed
Has Results |
PET Imaging of mGLuR5 With Drug Challenge |
- Major Depressive Disorder
- Post-Traumatic Stress Disorder (PTSD)
|
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Change in Glutamate Levels at Baseline and After Ketamine Administration as Confirmed by Positron Emission Tomography (PET) Imaging
|
79 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01691092 |
1111009365 |
|
June 2012 |
February 2016 |
February 2016 |
September 24, 2012 |
April 21, 2017 |
April 21, 2017 |
- Connecticut Mental Health Center
New Haven, Connecticut, United States - Yale University Magnetic Resonance Research Center (MRRC)
New Haven, Connecticut, United States - Yale University PET Center
New Haven, Connecticut, United States
|
|
| 80 |
NCT01824433 |
Completed |
Comparison of Venlafaxine and Fluoxetine in the Treatment of Postmenopausal Women With Major Depression |
|
- Drug: venlafaxine
- Drug: fluoxetine
|
Interventional
|
Phase 4 |
- Capital Medical University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overall Improvement
- Improvement of individual symptoms
|
189 |
Female |
50 Years to 80 Years (Adult, Older Adult) |
NCT01824433 |
VFPWMDD |
|
March 7, 2013 |
March 16, 2017 |
March 16, 2017 |
April 4, 2013 |
September 14, 2017 |
|
- Beijing Anding Hospital
Beijing, Beijing, China
|
|
| 81 |
NCT01244724 |
Terminated
Has Results |
Lexapro for Major Depression in Patients With Epilepsy |
|
|
Interventional
|
Phase 4 |
- Weill Medical College of Cornell University
- Forest Laboratories
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hamilton Depression Scale
- National Hospital Seizure Severity Scale
|
26 |
All |
18 Years and older (Adult, Older Adult) |
NCT01244724 |
LXP-MD-109 |
|
October 2007 |
December 2011 |
March 2012 |
November 19, 2010 |
July 11, 2018 |
August 3, 2015 |
- Weill Medical College of Cornell University
New York, New York, United States
|
|
| 82 |
NCT00067301 |
Completed |
PUFA Augmentation in Treatment of Major Depression |
|
- Drug: Polyunsaturated Fatty Acids (PUFA)
- Drug: Citalopram
|
Interventional
|
Phase 3 |
- National Center for Complementary and Integrative Health (NCCIH)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00067301 |
R21AT001077
GertsikL |
|
September 2003 |
April 2007 |
April 2007 |
August 15, 2003 |
January 25, 2008 |
|
- Cedars-Sinai Medical Center Dept. of Psychiatry
Los Angeles, California, United States
|
|
| 83 |
NCT00427128 |
Completed |
Prozac Treatment of Major Depression: Discontinuation Study |
|
- Drug: fluoxetine
- Drug: placebo
|
Interventional
|
Phase 4 |
- New York State Psychiatric Institute
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- MDD section of Mood Disorders Module of Structured Clinical Interview for DSM-IV (SCID)
- Ham-D
- CGI
|
627 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00427128 |
4099R
RO1 MH56058 |
|
November 1995 |
|
March 2003 |
January 26, 2007 |
December 15, 2011 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - New York State Psychiatric Institute
New York, New York, United States
|
|
| 84 |
NCT00917059 |
Completed |
Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study) |
|
- Drug: Escitalopram
- Drug: Bupropion XL
|
Interventional
|
Phase 4 |
- University of California, Los Angeles
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Score on Hamilton Depression Rating Scale (HAM-D)
- Score on Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30)
|
172 |
All |
21 Years to 75 Years (Adult, Older Adult) |
NCT00917059 |
R01MH085925
09-03-022-01
DSIR 84-CT |
|
May 2009 |
May 2012 |
May 2012 |
June 10, 2009 |
February 6, 2013 |
|
- UCLA Semel Institute
Los Angeles, California, United States
|
|
| 85 |
NCT00610506 |
Completed |
Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features |
|
|
Interventional
|
Phase 3 |
- Duke University
- Forest Laboratories
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- changes in HAM-D-29 scores from baseline to end of treatment.
- changes in 8-atypical items on the HAM-D-29, SDS and ESQ from baseline to end of treatment. Response will be defined as 50% or greater reduction in HAM-D-29 scores from baseline to end of treatment.
|
15 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00610506 |
7842
IRB#7842 |
|
October 2005 |
May 2007 |
May 2007 |
February 8, 2008 |
May 31, 2013 |
|
- Dept Psychiatry, Duke University Medical Center
Durham, North Carolina, United States
|
|
| 86 |
NCT00368303 |
Completed |
A Local Register Study For Major Depression Of Paroxetine Controlled Release |
- Depressive Disorder, Major
- Major Depressive Disorder (MDD)
|
- Drug: Paroxetine CR
- Drug: Paroxetine IR
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Scores on depression rating scale at treatment week 1,2,3,4,6 and 8.
- Scores on clinical impression severity and improvement items at treatment week 1, 2,3,4,6,8
|
362 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00368303 |
PCR103124 |
|
December 2006 |
|
|
August 24, 2006 |
June 4, 2012 |
|
- GSK Investigational Site
Guangzhou, Guangdong, China - GSK Investigational Site
Baoding, Hebei, China - GSK Investigational Site
Changsha, Hunan, China - (and 8 more...)
|
|
| 87 |
NCT00517764 |
Completed |
Childhood Adversity, Genetic Polymorphisms and Stress in First Onset Major Depression |
|
|
Interventional
|
Not Applicable |
- Centre for Addiction and Mental Health
- Queen's University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hamilton Rating Scale for Depression (HRDS)
|
299 |
All |
16 Years to 29 Years (Child, Adult) |
NCT00517764 |
155/2006 |
|
December 2006 |
June 2013 |
June 2013 |
August 17, 2007 |
August 9, 2013 |
|
- Queens University
Kingston, Ontario, Canada - Centre for Addiction and Mental Health
Toronto, Ontario, Canada
|
|
| 88 |
NCT01377194 |
Completed
Has Results |
Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Levomilnacipran ER
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score - Mixed-effects Model for Repeated Measures (MMRM) Analysis.
- Change in Sheehan Disability Scale (SDS) Total Score
|
568 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01377194 |
LVM-MD-10 |
|
June 2011 |
March 2012 |
March 2012 |
June 21, 2011 |
October 29, 2013 |
October 29, 2013 |
- Forest Investigative Site 039
Birmingham, Alabama, United States - Forest Investigative Site 037
Beverly Hills, California, United States - Forest Investigative Site 012
Encino, California, United States - (and 48 more...)
|
|
| 89 |
NCT00744406 |
Completed |
Patient Dimensions as Predictors of Varied Treatment Responses and Outcomes in Patients With Major Depression |
- Depression
- Major Depressive Disorder
|
- Behavioral: Cognitive Behavioral Therapy
- Behavioral: Interpersonal Therapy
- Drug: Antidepressant medication (sertraline ,paroxetineor or venlafaxine)
|
Interventional
|
Phase 2 |
- Centre for Addiction and Mental Health
- Ontario Mental Health Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale
|
72 |
All |
18 Years to 60 Years (Adult) |
NCT00744406 |
160/2001 |
|
July 2003 |
September 2006 |
|
September 1, 2008 |
September 1, 2008 |
|
- Centre for Addiction and Mental Health
Toronto, Ontario, Canada
|
|
| 90 |
NCT01034462 |
Completed
Has Results |
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Levomilnacipran ER
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
- Change in Sheehan Disability Scale (SDS) Total Score
|
442 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT01034462 |
LVM-MD-03 |
|
December 2009 |
December 2011 |
December 2011 |
December 17, 2009 |
October 25, 2013 |
October 25, 2013 |
- Forest Investigative Site 055
Dothan, Alabama, United States - Forest Investigative Site 065
Highlands Ranch, Colorado, United States - Forest Investigative Site 057
Boca Raton, Florida, United States - (and 20 more...)
|
|
| 91 |
NCT00101452 |
Completed
Has Results |
Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression |
|
- Drug: S-adenosyl-l-methionine
- Drug: Escitalopram
- Drug: Placebo
|
Interventional
|
Not Applicable |
- Maurizio Fava, MD
- National Center for Complementary and Integrative Health (NCCIH)
- Massachusetts General Hospital
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Hamilton Rating Scale for Depression (HAM-D)
|
199 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00101452 |
R01AT001638-01A1 |
|
April 2005 |
June 2010 |
June 2010 |
January 11, 2005 |
April 4, 2017 |
December 31, 2012 |
- Massachusetts General Hospital
Boston, Massachusetts, United States - Butler Hospital
Providence, Rhode Island, United States
|
|
| 92 |
NCT00969709 |
Completed
Has Results |
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Levomilnacipran ER
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
- Change in Sheehan Disability Scale (SDS) Total Score
|
724 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00969709 |
LVM-MD-01 |
|
September 2009 |
May 2011 |
|
September 1, 2009 |
October 25, 2013 |
October 25, 2013 |
- Forest Investigative Site
Phoenix, Arizona, United States - Forest Investigative Site
Scottsdale, Arizona, United States - Forest Investigative Site
Beverly Hills, California, United States - (and 35 more...)
|
|
| 93 |
NCT00969150 |
Completed
Has Results |
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Levomilnacipran ER
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
- Change in Sheehan Disability Scale (SDS) Total Score
|
362 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00969150 |
LVM-MD-02 |
|
September 2009 |
November 2010 |
|
September 1, 2009 |
October 25, 2013 |
October 25, 2013 |
- Forest Investigative Site
Scottsdale, Arizona, United States - Forest Investigative Site
Encino, California, United States - Forest Investigative Site
Los Alamitos, California, United States - (and 22 more...)
|
|
| 94 |
NCT01473381 |
Completed
Has Results |
Safety and Efficacy of Vilazodone in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Vilazodone
- Drug: Placebo to citalopram
- Drug: Placebo to vilazodone
- Drug: Citalopram
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 10
- Change From Baseline to Week 10 in the Clinical Global Impressions-Severity (CGI-S) Scale Score
- Percentage of Participants With a Montgomery-Åsberg Depression Rating Scale (MADRS) Sustained Response
|
1162 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01473381 |
VLZ-MD-01 |
VLZ-MD-01 |
December 2011 |
June 2013 |
June 2013 |
November 17, 2011 |
August 8, 2014 |
August 8, 2014 |
- Forest Investigative Site 036
Birmingham, Alabama, United States - Forest Investigative Site 016
Dothan, Alabama, United States - Forest Investigative Site 033
Scottsdale, Arizona, United States - (and 51 more...)
|
|
| 95 |
NCT00420004 |
Completed
Has Results |
A Study for Participants With Major Depression |
- Major Depressive Disorder
|
- Drug: LY2216684
- Drug: Placebo
- Drug: Escitalopram
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline to Week 8 in the 17-item Hamilton Depression Rating Scale (HAMD-17) Total Score
- Change From Baseline to Week 8 in Maier-Philipp Subscale of the 17-item Hamilton Depression Rating Scale (HAMD-17)
- Response and Remission Rates
- (and 16 more...)
|
469 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00420004 |
11174
H9P-MC-LNBD |
|
December 2006 |
March 2008 |
March 2008 |
January 9, 2007 |
April 27, 2018 |
April 27, 2018 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Orlando, Florida, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Prairie Village, Kansas, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Allentown, Pennsylvania, United States - (and 4 more...)
|
|
| 96 |
NCT01421342 |
Completed
Has Results |
VA Augmentation and Switching Treatments for Improving Depression Outcomes |
- Major Depressive Disorder
|
- Drug: Switching: Bupropion-SR
- Drug: Augmenting: Antidepressant + Bupropion-SR
- Drug: Augmenting: Antidepressant + Aripiprazole
|
Interventional
|
Phase 3 |
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of Protocol Remission of Symptoms of Major Depressive Disorder
- Rate of Protocol Relapse of Symptoms of Major Depression After Achieving Remission in the Acute Phase
- Rate of Protocol Response as Reduction in Symptoms of Major Depression (>= 50% Reduction in QIDS-C)
- Rate of Protocol Response Measured as a Change in Clinical Global Impression (CGI) - Improvement Scale
|
1522 |
All |
18 Years and older (Adult, Older Adult) |
NCT01421342 |
576 |
VAST-D |
December 2012 |
August 2015 |
June 2016 |
August 22, 2011 |
May 28, 2018 |
May 28, 2018 |
- Tuscaloosa VA Medical Center, Tuscaloosa, AL
Tuscaloosa, Alabama, United States - Phoenix VA Health Care System, Phoenix, AZ
Phoenix, Arizona, United States - Southern Arizona VA Health Care System, Tucson
Tucson, Arizona, United States - (and 32 more...)
|
|
| 97 |
NCT00568672 |
Withdrawn |
Optimal Duration of Olanzapine Add-on Therapy in Major Depression |
- Relapse Rate of a Major Depressive Episode
- Safety of Olanzapine in Subjects With Major Depression
|
|
Interventional
|
Phase 3 |
- Charite University, Berlin, Germany
- Eli Lilly and Company
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Relapse Rate, Hamilton Depression Rating Scale (17 item version)
- Safety and side effect scales (SWN Scale, CGI), Beck Depression Inventory
|
30 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00568672 |
2007-000512-82
Franziska Jakob, MD
Ion Anghelescu, MD |
OLA-D |
October 2007 |
|
April 2008 |
December 6, 2007 |
April 25, 2008 |
|
- Departement of Psychiatry and Psychotherapy, Charite, University Medicine Berlin, Campus Benjamin Franklin
Berlin, Germany
|
|
| 98 |
NCT01305707 |
Terminated |
Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression |
|
- Device: C-ECT
- Drug: PHARMACOTHERAPY
|
Interventional
|
Phase 4 |
- Hospital Universitari de Bellvitge
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Hamilton Depression Rating Scale 21 items (HDRS-21)
- Mini-Mental State Examination (MMSE 35)
- UKU - Adverse effects rating scales
- (and 9 more...)
|
104 |
All |
18 Years and older (Adult, Older Adult) |
NCT01305707 |
TECHUB2007 |
|
July 2009 |
July 2014 |
July 2014 |
March 1, 2011 |
August 31, 2015 |
|
- Hospital Universitari de Bellvitge
Hospitalet de Llobregat, Barcelona, Spain - Corporació Sanitària Parc Tauli
Sabadell, Barcelona, Spain - Hospital Universitari de Bellvitge, IDIBELL
Barcelona, Spain
|
|
| 99 |
NCT01741142 |
Terminated |
Efficacy and Safety Study of ABT-436 in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: ABT-436
- Drug: Escitalopram
- Drug: Placebo
|
Interventional
|
Phase 2 |
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Primary efficacy variable will be change from baseline to Week 6 visit on Montgomery-Asberg Depression Rating Scale (MADRS) total score.
- Secondary efficacy variables include change from Baseline to Week 6 on clinician-rated Hamilton Depression Rating Scale.
|
19 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01741142 |
M11-733 |
|
January 2012 |
October 2013 |
August 2015 |
December 4, 2012 |
October 8, 2013 |
|
- Site Reference ID/Investigator# 85593
Little Rock, Arkansas, United States - Site Reference ID/Investigator# 87228
Garden Grove, California, United States - Site Reference ID/Investigator# 87214
National City, California, United States - (and 15 more...)
|
|
| 100 |
NCT01049347 |
Completed |
Amitriptyline and Paroxetine Treatment of Major Depression |
|
- Drug: amitriptyline
- Drug: paroxetine
|
Interventional
|
Phase 3 |
- Central Institute of Mental Health, Mannheim
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale (21-item version)
- cortisol in saliva (8.00, 16.00, 22.00) during wash-out (6 days) and 35 days of treatment
|
127 |
All |
18 Years and older (Adult, Older Adult) |
NCT01049347 |
AmiPar
DFG De 660/1-1 |
|
October 1997 |
May 2000 |
May 2000 |
January 14, 2010 |
January 14, 2010 |
|
- Central Institute of Mental Health
Mannheim, Germany
|
|
Create an RSS feed from your search for:
Download the search results for: